High Prevalence of Cryptococcal Antigenemia among HIV-infected Patients Receiving Antiretroviral Therapy in Ethiopia

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Alemu, Abere Shiferaw ^a   Kempker, Russell R ^b   Tenna, Admasu ^c   Smitson, Christopher ^b   Berhe, Nega ^c   Fekade, Daniel ^c   Blumberg, Henry M ^b,d   Aseffa, Abraham ^e  

^a Haramya University   (Ethiopia)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ADDIS ABABA UNIVERSITY   (Ethiopia)

^d EMORY UNIVERSITY   (United States)

^e ARMAUER HANSEN RESEARCH INSTITUTE   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ANTIGENICITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CRYPTOCOCCAL ANTIGENEMIA; CRYPTOCOCCOSIS; ETHIOPIA; FEMALE; FEVER; HEADACHE; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MORTALITY; NIGHT SWEAT; PHOTOPHOBIA; PNEUMONIA; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; SELF REPORT; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; TREATMENT DURATION;

ADULT; ANTI-HIV AGENTS; ANTIGENS, FUNGAL; CD4 LYMPHOCYTE COUNT; COMORBIDITY; CRYPTOCOCCUS; ETHIOPIA; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; MULTIVARIATE ANALYSIS; PREVALENCE; RISK FACTORS;

EID: 84874627060     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058377     Document Type: Article

References (17)

1. WHO (2011) Rapid Advice: Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-infected Adults, Adolescents and Children. Geneva, World Health Organization.
2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
3. Rajasingham R, Meya DB, Boulware DR, (2012) Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 59: e85-91.
4. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, et al. (2009) Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 48: 856-862.
5. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, et al. (2007) Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 12: 929-935.
6. Micol R, Lortholary O, Sar B, Laureillard D, Ngeth C, et al. (2007) Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 45: 555-559.
7. Pongsai P, Atamasirikul K, Sungkanuparph S, (2010) The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. J Infect 60: 474-477.
8. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, et al. (2010) Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 51: 448-455.
9. French N, Gray K, Watera C, Nakiyingi J, Lugada E, et al. (2002) Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 16: 1031-1038.
10. Federal Ministry of Health (2010) Report on progress towards implementation of the UN Declaration of Commitment on HIV/AIDS. Addis Ababa: Federal HIV/AIDS Prevention and Control Office.
11. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, et al. (2009) Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42: 377-381.
12. Hosmer DW, Lemeshow S (2000) Applied logistic regression. 2nd ed. New York: Wiley.
13. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, et al. (2011) Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 53: 1019-1023.
14. Lindsley MD, Mekha N, Baggett HC, Surinthong Y, Autthateinchai R, et al. (2011) Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis 53: 321-325.
15. Chowdhary A, Rhandhawa HS, Prakash A, Meis JF, (2012) Environmental prevalence of Cryptococcus neoformans and Cryptococcus gattii in India: an update. Crit Rev Microbiol 38: 1-16.
16. Ellis DH, Pfeiffer TJ, (1990) Ecology, life cycle, and infectious propagule of Cryptococcus neoformans. Lancet 336: 923-925.
17. Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, et al. (2011) Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 8: e1000391.